4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $36.00 price target on the stock. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ FY2029 earnings at ($1.81) EPS.

A number of other equities research analysts have also recently issued reports on FDMT. Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. Bank of America decreased their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Chardan Capital reaffirmed a “buy” rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Royal Bank of Canada reduced their price objective on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Finally, Morgan Stanley started coverage on shares of 4D Molecular Therapeutics in a research report on Thursday, November 21st. They set an “underweight” rating and a $8.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.56.

4D Molecular Therapeutics Trading Up 3.3 %

NASDAQ FDMT opened at $5.04 on Monday. 4D Molecular Therapeutics has a 1 year low of $4.68 and a 1 year high of $36.25. The company has a fifty day simple moving average of $6.87 and a 200 day simple moving average of $11.77. The company has a market cap of $232.99 million, a P/E ratio of -1.77 and a beta of 2.81.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FDMT. Assenagon Asset Management S.A. raised its position in 4D Molecular Therapeutics by 238.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock worth $16,684,000 after purchasing an additional 1,087,147 shares in the last quarter. Braidwell LP raised its holdings in shares of 4D Molecular Therapeutics by 231.7% in the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after buying an additional 855,990 shares in the last quarter. Redmile Group LLC raised its holdings in shares of 4D Molecular Therapeutics by 17.6% in the 3rd quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock worth $13,643,000 after buying an additional 188,655 shares in the last quarter. Novo Holdings A S boosted its stake in 4D Molecular Therapeutics by 7.1% in the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after buying an additional 100,000 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its stake in 4D Molecular Therapeutics by 652.7% in the 2nd quarter. Squarepoint Ops LLC now owns 110,041 shares of the company’s stock valued at $2,310,000 after buying an additional 95,422 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.